Supplementary appendix
|
|
- Quentin O’Brien’
- 5 years ago
- Views:
Transcription
1 Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Chandran SS, Somerville RPT, Yang JC, et al. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncol 2017; published online April 7.
2 Supplementary Figure Appendix p.1 NCT Adoptive transfer trial design Non-myeloablative lymphocyte depleting preparative regimen: Cyclophosphamide (60 mg/kg/day intravenous X 2 days) Fludarabine (25 mg/m 2 /day intravenous X 5 days) Intravenous infusion of TIL Intravenous high-dose IL-2 NCT Adoptive transfer trial design. Beginning on day -7, patients received a nonmyeloablative lymphodepleting conditioning chemotherapy regimen consisting of intravenous cyclophosphamide (Cy, 60 mg/kg) daily for 2 days followed by fludarabine (25 mg/m 2 ) daily for 5 days. One day after completion of their preparative regimen, patients received expanded autologous TIL intravenously (day 0), followed by high-dose IL-2 (720,000 IU/kg) every 8 hours to tolerance. 1
3 Supplementary Figure. CONSORT diagram of enrollment Appendix p.2 Eligible and Consented for Metastasectomy (n=27) Underwent Successful Metastasectomy (n=27) Excluded Due to Insufficient TIL expansion (n=1) No TIL identified in tumor after prior Yttrium bead therapy Successful TIL Expansion (n=26; 96%) Ineligible for TIL Therapy (n=2) New clinically significant cardiac metastasis (n=1) Patient refused therapy (n=1) TIL Reactivity Insufficient (n=3) Treated with TIL Therapy (n=21) 2
4 Supplementary Table. Additional Patient Related Characteristics Appendix p.3 Pt No. Age (yrs) Sex Primary Ocular Tumor Time between primary and met disease (yrs) Time between diagnosis of met disease and TIL therapy (yrs) BAP-1 Status AJCC M stage for Uveal Melanoma Maximum individual tumor diameter (cm) LDH (U/L)* Alk Phos (U/L)* 1 55 F Uveal Wild type M1c F Uveal Wild type M1a M Uveal Mutated M1c M Uveal Wild type M1c F Uveal Wild type M1c F Uveal Wild type M1b M Uveal Mutated M1c M Uveal Wild type M1b M Uveal Mutated M1c F Uveal Mutated M1c F Uveal Mutated M1a M Uveal Wild type M1b F Uveal Wild type M1b F Uveal Wild type M1b M Uveal Wild type M1c M Uveal Wild type M1b M Uveal Wild type M1b M Uveal Wild type M1b M Uveal Mutated M1a M Uveal Mutated M1b M Uveal Mutated M1b *Bolded indicate elevated values Normal ranges: Lactate Dehydrogenase (LDH) U/L Alkaline Phosphatase (Alk Phos) U/L 3
5 Supplementary Figure Appendix p.4 A. B. Administered TIL have predominantly an effector memory (T EM ) phenotype. (A) Phenotype of infused CD8+ and (B) CD4+ T cells in the administered TIL products of metastatic uveal melanoma patients (n=21). Infused TIL underwent flow cytometric analysis to determine the expression of indicated differentiation states: Naïve (CD45RO-CD62L+), central memory (T CM :CD45RO+CD62L+), effector memory (T EM :CD45RO+CD62L-), effector memory RA (T EMRA :CD45RA+CD45RO-CD62L-). Shown are the percentage of live CD3+ gated CD4+ or CD8+ cells staining with the respective markers compared to isotype control. Each dot represents an individual TIL infusion product. The bar represents the mean. 4
6 Supplementary Figure Appendix p.5 In vitro flow cytometric assessment of tumor reactive T cell frequency. The frequency of tumor-reactive T cells within the TIL infusion product was determined by the sum of the flow cytometric measurements of the T cell activation markers, OX40 (CD134) on CD4+ T cells and 4-1BB (CD137) on CD8+ T cells following overnight co-culture with cryopreserved autologous tumor digests minus the background frequency seen against autologous APCs (negative control). Shown are representative flow cytometry plots used to calculate the tumor-reactive T cell frequency in the TIL of Patients #3 and #10. 5
7 Supplementary Figure Appendix p IFN- (pg/ml) R 2 = 0.91 P < % tumor reactive T cells (OX40+CD4+CD3+) + (4-1BB+CD8+CD3+) Correlation between flow cytometric and ELISA based assessment of tumor reactivity in administered TIL. The frequency of tumor reactive T cells in the TIL infusion products (n=18) was determined by flow cytometric measurement of tumor induced T cell activation markers. The % tumor reactive T cells was calculated from the sum of the frequency of OX40+CD4+CD3+ cells and 4-1BB+CD8+CD3+ cells in response to autologous tumor stimulation (minus background reactivity against autologous APCs). The supernatant from these respective co-cultures was assessed by ELISA to determine the tumor induced IFN-g cytokine production. Correlation analysis was used to quantify the relationship between the flow cytometric and ELISA parameters and is presented as R 2 values with their significance (P) level. Each dot represents an individual analyzed TIL infusion product. Each data point represents the mean of triplicate technical measurements from ELISA and flow cytometric assays and are representative of two independent tests with similar results. 6
Supplementary Figure 1. Characterization of basophils after reconstitution of SCID mice
Supplementary figure legends Supplementary Figure 1. Characterization of after reconstitution of SCID mice with CD4 + CD62L + T cells. (A-C) SCID mice (n = 6 / group) were reconstituted with 2 x 1 6 CD4
More informationDEVELOPMENT OF CELLULAR IMMUNOLOGY
DEVELOPMENT OF CELLULAR IMMUNOLOGY 1880 s: Antibodies described (dominated studies of immunology until 1960 s) 1958: Journal of Immunology (137 papers) lymphocyte not listed in index Two papers on transfer
More informationAdoptive T Cell Therapy TILs & TCRs & CARs
Adoptive T Cell Therapy TILs & TCRs & CARs Inge Marie Svane CCIT DENMARK Professor, MD Center for Cancer Immune Therapy Department of Oncology, Herlev Hospital Copenhagen University Denmark Therapeutic
More informationCorporate Presentation
Corporate Presentation June 2017 Forward-Looking Statements This presentation contains forward-looking statements reflecting management s current beliefs and expectations. These forward looking statements
More informationSupporting Information
Supporting Information Chapuis et al. 10.1073/pnas.1113748109 SI Methods Selection of Patients, Targets, Isolation, and Expansion of Melanoma- Specific CTL Clones. Patients were HLA-typed, and their tumors
More informationx Lymphocyte count /µl CD8+ count/µl 800 Calculated
% Lymphocyte in CBC A. 50 40 30 20 10 Lymphocyte count /µl B. x10 3 2.5 1.5 C. 50 D. 1000 % CD3+CD8+ Cells 40 30 20 Calculated CD8+ count/µl 800 600 400 200 10 0 #61 #63 #64 #65 #68 #71 #72 #75 Figure
More informationExploiting tumour infiltrating lymphocytes (TILs) as a therapeutic strategy in epithelial ovarian cancer
Exploiting tumour infiltrating lymphocytes (TILs) as a therapeutic strategy in epithelial ovarian cancer G.L.Owens 1,2, V.Sheard 2, M.Price 1, D.E.Gilham 2, R.J.Edmondson 1 1 Gynaecological Oncology Research
More informationSupplementary Data. Treg phenotype
Supplementary Data Additional Experiment An additional experiment was performed using cryopreserved peripheral blood mononuclear cells (PBMC) derived from five renal cell carcinoma (RCC) patients [see
More informationSupplementary Figure 1. Example of gating strategy
Supplementary Figure 1. Example of gating strategy Legend Supplementary Figure 1: First, gating is performed to include only single cells (singlets) (A) and CD3+ cells (B). After gating on the lymphocyte
More informationSupplementary Figure 1
Supplementary Figure 1 Identification of IFN-γ-producing CD8 + and CD4 + T cells with naive phenotype by alternative gating and sample-processing strategies. a. Contour 5% probability plots show definition
More informationSupplemental materials
Supplemental materials 1 Supplemental Fig. 1 Immunogram This immunogram summarizes patient clinical data and immune parameters at corresponding time points for Patient IMF-32. The top panel illustrates
More informationAdvances in Adoptive Cellular Therapy of Cancer. Melanoma Bridge Meeting December 5, 2014
Advances in Adoptive Cellular Therapy of Cancer Melanoma Bridge Meeting December 5, 2014 David Stroncek, MD Chief, Cell Processing Section, DTM, CC, NIH Bethesda, Maryland, USA Disclosures None Focus
More informationSupplementary Figure 1. mrna expression of chitinase and chitinase-like protein in splenic immune cells. Each splenic immune cell population was
Supplementary Figure 1. mrna expression of chitinase and chitinase-like protein in splenic immune cells. Each splenic immune cell population was sorted by FACS. Surface markers for sorting were CD11c +
More informationDual Targeting Nanoparticle Stimulates the Immune
Dual Targeting Nanoparticle Stimulates the Immune System to Inhibit Tumor Growth Alyssa K. Kosmides, John-William Sidhom, Andrew Fraser, Catherine A. Bessell, Jonathan P. Schneck * Supplemental Figure
More informationThe encephalitogenicity of TH17 cells is dependent on IL-1- and IL-23- induced production of the cytokine GM-CSF
CORRECTION NOTICE Nat.Immunol. 12, 568 575 (2011) The encephalitogenicity of TH17 cells is dependent on IL-1- and IL-23- induced production of the cytokine GM-CSF Mohamed El-Behi, Bogoljub Ciric, Hong
More informationAdoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option
Rohaan et al. Journal for ImmunoTherapy of Cancer (2018) 6:102 https://doi.org/10.1186/s40425-018-0391-1 REVIEW Adoptive transfer of tumor-infiltrating lymphocytes in : a viable treatment option Maartje
More informationSupplemental Figure 1
Supplemental Figure 1 1a 1c PD-1 MFI fold change 6 5 4 3 2 1 IL-1α IL-2 IL-4 IL-6 IL-1 IL-12 IL-13 IL-15 IL-17 IL-18 IL-21 IL-23 IFN-α Mut Human PD-1 promoter SBE-D 5 -GTCTG- -1.2kb SBE-P -CAGAC- -1.kb
More information<10. IL-1β IL-6 TNF + _ TGF-β + IL-23
3 ns 25 ns 2 IL-17 (pg/ml) 15 1 ns ns 5 IL-1β IL-6 TNF
More informationDefective STAT1 activation associated with impaired IFN-g production in NK and T lymphocytes from metastatic melanoma patients treated with IL-2
Defective STAT1 activation associated with impaired IFN-g production in NK and T lymphocytes from metastatic melanoma patients treated with IL-2 SUPPLEMENTARY FIGURES AND TABLES Supplementary Figure S1:
More informationLow Avidity CMV + T Cells accumulate in Old Humans
Supplementary Figure Legends Supplementary Figure 1. CD45RA expressing CMVpp65-specific T cell populations accumulate within HLA-A*0201 and HLA-B*0701 individuals Pooled data showing the size of the NLV/HLA-A*0201-specific
More informationThe CAPRI-T was one of two (along with the CAPRI-NK, see reference. [29]) basic immunological studies nested within the CAMELIA trial.
1 SUPPLEMENTARY INFORMATION Patient description and recruitment The CAPRI-T was one of two (along with the CAPRI-NK, see reference [29]) basic immunological studies nested within the CAMELIA trial. Patients
More informationsupplemental Figure 1
supplemental Figure 1 A T cell T1 anti-ny-eso-117-16/hla-a*:1 CDζ CH/CH scfv B T cell T1 anti-ny-eso-117-16/hla-a*:1 CDζ CH/CH scfv C T cell BW1/6 anti-cea CDζ CH/CH scfv supplemental Figure 1.79.9.87
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationGeneration of ST2-GFP reporter mice and characterization of ILC1 cells following infection
Supplementary Figure 1 Generation of ST2-GFP reporter mice and characterization of ILC1 cells following infection with influenza virus. (a) ST2-GFP reporter mice were generated as described in Methods.
More informationSupplementary Fig. 1 p38 MAPK negatively regulates DC differentiation. (a) Western blot analysis of p38 isoform expression in BM cells, immature DCs
Supplementary Fig. 1 p38 MAPK negatively regulates DC differentiation. (a) Western blot analysis of p38 isoform expression in BM cells, immature DCs (idcs) and mature DCs (mdcs). A myeloma cell line expressing
More informationILC1 and ILC3 isolation and culture Following cell sorting, we confirmed that the recovered cells belonged to the ILC1, ILC2 and
Supplementary Methods and isolation and culture Following cell sorting, we confirmed that the recovered cells belonged to the, ILC2 and subsets. For this purpose we performed intracellular flow cytometry
More informationNK cell flow cytometric assay In vivo DC viability and migration assay
NK cell flow cytometric assay 6 NK cells were purified, by negative selection with the NK Cell Isolation Kit (Miltenyi iotec), from spleen and lymph nodes of 6 RAG1KO mice, injected the day before with
More informationOverview 4/11/2013. Cell Kinetics in Adoptive Cell Therapy. April 11, 2013
Cell Kinetics in Adoptive Cell Therapy April 11, 2013 David Stroncek, MD Chief, Cellular Processing Section DTM, CC, NIH Cellular Therapies Cell suspensions used for therapeutic purposes Examples Red Cells
More informationRichard P Junghans, PhD, MD
CANCER GENE THERAPY WITH DESIGNER T CELLS: TOXICITY VERSUS ACTIVITY Richard P Junghans, PhD, MD Director, Biotherapeutics Development Lab Associate Professor of Surgery and Medicine Boston University School
More informationSupplemental Information. Phase 1 Results of ZUMA-1: A Multicenter Study. of KTE-C19 Anti-CD19 CAR T Cell Therapy. in Refractory Aggressive Lymphoma
YMTHE, Volume 25 Supplemental Information Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma Frederick L. Locke, Sattva S. Neelapu,
More informationTherapeutic PD L1 and LAG 3 blockade rapidly clears established blood stage Plasmodium infection
Supplementary Information Therapeutic PD L1 and LAG 3 blockade rapidly clears established blood stage Plasmodium infection Noah S. Butler, Jacqueline Moebius, Lecia L. Pewe, Boubacar Traore, Ogobara K.
More informationThe Immune System. Innate. Adaptive. - skin, mucosal barriers - complement - neutrophils, NK cells, mast cells, basophils, eosinophils
Objectives - explain the rationale behind cellular adoptive immunotherapy - describe methods of improving cellular adoptive immunotherapy - identify mechanisms of tumor escape from cellular adoptive immunotherapy
More informationNew insights into CD8+ T cell function and regulation. Pam Ohashi Princess Margaret Cancer Centre
New insights into CD8+ T cell function and regulation Pam Ohashi Princess Margaret Cancer Centre New insights into CD8+ T cell function and regulation Pam Ohashi Princess Margaret Cancer Centre No Disclosures
More informationSupplementary Figures
Supplementary Figures Supplementary Fig. 1. Surface thiol groups and reduction of activated T cells. (a) Activated CD8 + T-cells have high expression levels of free thiol groups on cell surface proteins.
More informationAdoptive Cellular Therapy SITC Primer October 2012
Adoptive Cellular Therapy SITC Primer October 2012 Cassian Yee MD Member Fred Hutchinson Cancer Research Center Program in Immunology Clinical Research Division Professor University of Washington Division
More informationSupplementary Figure 1
Supplementary Figure 1 # nonsynonymous mutations (tngs, 1561 genes) 600 p=0.056 500 250 200 150 100 50 0 HLA-DR (-) HLA-DR (+) Supplementary Figure 1: HLA-DR(+) melanoma cell lines are associated with
More informationImmunotransplant for Mantle Cell Lymphoma: A phase I/II study demonstrating amplification of tumor-reactive T cells
Immunotransplant for Mantle Cell Lymphoma: A phase I/II study demonstrating amplification of tumor-reactive T cells Joshua Brody MD Division of Oncology Stanford University Medical Center Presenter Disclosure
More informationSupplementary Fig. 1: Ex vivo tetramer enrichment with anti-c-myc beads
Supplementary Fig. 1: Ex vivo tetramer enrichment with anti-c-myc beads Representative example of comparative ex vivo tetramer enrichment performed in three independent experiments with either conventional
More informationBrain mets under I.O.
Brain mets under I.O. Bernard Escudier Gustave Roussy, Villejuif, France Disclosure Honorarium received from BMS, Novartis, Pfizer, Bayer, Roche, Exelixis, Ipsen, Eisai, Calithera Travel Grant from BMS,
More informationSUPPLEMENTAL MATERIAL. Number of patients 14
SUPPLEMENTAL MATERIAL Supplemental Table 1 Number of patients 14 Age, years 54.9 ± 10.0 Female gender, n (%) 6 (42.9) Diabetes, n (%) 2 (14.3) History of hypertension, n (%) 5 (35.7) Ever smoker, n (%)
More informationIdera Pharmaceuticals
Idera Pharmaceuticals ILLUMINATE-204 Clinical Data Update December 2018 Forward Looking Statements and Other Important Cautions This presentation contains forward-looking statements within the meaning
More informationCell Therapy Liaison Meeting. Carl June, M.D.
Cell Therapy Liaison Meeting Personalized Medicine Carl June, M.D. Professor of Pathology and Lab Medicine Abramson Cancer Center University of Pennsylvania October 17, 2008 AABB Headquarters Bethesda,
More informationSUPPLEMENTARY FIGURE 1
SUPPLEMENTARY FIGURE 1 A LN Cell count (1 ) 1 3 1 CD+ 1 1 CDL lo CD hi 1 CD+FoxP3+ 1 1 1 7 3 3 3 % of cells 9 7 7 % of cells CD+ 3 1 % of cells CDL lo CD hi 1 1 % of CD+ cells CD+FoxP3+ 3 1 % of CD+ T
More informationThe toll-like receptor 4 ligands Mrp8 and Mrp14 play a critical role in the development of autoreactive CD8 + T cells
1 SUPPLEMENTARY INFORMATION The toll-like receptor 4 ligands Mrp8 and Mrp14 play a critical role in the development of autoreactive CD8 + T cells Karin Loser 1,2,6, Thomas Vogl 2,3, Maik Voskort 1, Aloys
More informationRestoring Immune Function of Tumor-Specific CD4 + T Cells during Recurrence of Melanoma
Restoring Immune Function of Tumor-Specific CD4 + T Cells during Recurrence of Melanoma Goding SR et al. J Immunol 2013; 190:4899-4909 C. Nikolowsky Christian Doppler Laboratory for Cardiac and Thoracic
More informationAdoptive T Cell Therapy Metastatic Melanoma
Adoptive T Cell Therapy Metastatic Melanoma Rikke Andersen MD, PhD student Center for Cancer Immune Therapy Department of Oncology, Herlev Hospital Copenhagen University Denmark Adoptive T Cell Therapy
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationSTATE OF THE ART 4: Combination Immune Therapy-Chemotherapy. Elizabeth M. Jaffee (JHU) James Yang (NCI) Jared Gollob (Duke) John Kirkwood (UPMI)
STATE OF THE ART 4: Combination Immune Therapy-Chemotherapy Elizabeth M. Jaffee (JHU) James Yang (NCI) Jared Gollob (Duke) John Kirkwood (UPMI) Topics for Consideration What are the rules for integrating
More informationB220 CD4 CD8. Figure 1. Confocal Image of Sensitized HLN. Representative image of a sensitized HLN
B220 CD4 CD8 Natarajan et al., unpublished data Figure 1. Confocal Image of Sensitized HLN. Representative image of a sensitized HLN showing B cell follicles and T cell areas. 20 µm thick. Image of magnification
More informationBlocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD-
Supplementary Methods Blocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD- L1 (10F.9G2, rat IgG2b, k), and PD-L2 (3.2, mouse IgG1) have been described (24). Anti-CTLA-4 (clone
More informationSupplementary Figure Legends. group) and analyzed for Siglec-G expression utilizing a monoclonal antibody to Siglec-G (clone SH2.1).
Supplementary Figure Legends Supplemental Figure : Naïve T cells express Siglec-G. Splenocytes were isolated from WT B or Siglec-G -/- animals that have not been transplanted (n= per group) and analyzed
More informationObjectives. Emily Whitehead 10/11/2018. Chimeric Antigen Recepetor T-Cells (CAR-T) CAR-T Therapy: The Past, The Present, and The Future
Objectives CAR-T Therapy: The Past, The Present, and The Future Nilay Shah, MD Michael Chargualaf, PharmD, BCOP WVU Medicine Mary Babb Randolph Cancer Center Review indications for FDA approved CAR-T therapy
More informationAdoptive cell therapy using genetically modified antigen-presenting cells
Adoptive cell therapy using genetically modified antigen-presenting cells Naoto Hirano Ontario Cancer Institute Princess Margaret Cancer Centre University of Toronto UofT-USP Oncology Conference November
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationSupplementary Information
Supplementary Information High throughput epitope discovery reveals frequent recognition of neo-antigens by CD4 + T-cells in human melanoma Carsten Linnemann, Marit M. van Buuren, Laura Bies, Els M.E.Verdegaal,
More informationCAR-T Therapy: The Past, The Present, and The Future. Nilay Shah, MD Michael Chargualaf, PharmD, BCOP WVU Medicine Mary Babb Randolph Cancer Center
CAR-T Therapy: The Past, The Present, and The Future Nilay Shah, MD Michael Chargualaf, PharmD, BCOP WVU Medicine Mary Babb Randolph Cancer Center Objectives Review indications for FDA approved CAR-T therapy
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationSupplementary Online Content
Supplementary Online Content Venook AP, Niedzwiecki D, Lenz H-J, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced
More informationState of the art: CAR-T cell therapy in lymphoma
State of the art: CAR-T cell therapy in lymphoma 14 th annual California Cancer Consortium conference Tanya Siddiqi, MD City of Hope Medical Center 8/11/18 Financial disclosures Consultant for Juno therapeutics
More informationOverview 3/31/2016. Cell Kinetics in Adoptive Cell Therapy. March 31, 2016
Cell Kinetics in Adoptive Cell Therapy March 31, 2016 David Stroncek, MD Chief, Cellular Processing Section DTM, CC, NIH Cellular Therapies Cell suspensions used for therapeutic purposes Examples Red Cells
More informationCell Kinetics in Adoptive Cell Therapy. March 31, 2016
Cell Kinetics in Adoptive Cell Therapy March 31, 2016 David Stroncek, MD Chief, Cellular Processing Section DTM, CC, NIH 1 Cellular Therapies Cell suspensions used for therapeutic purposes Examples Red
More informationLecture 17: Vaccines (Therapeutic and Prophylactic Types)
Lecture 17: Vaccines (Therapeutic and Prophylactic Types) Therapeutic vaccines Bacillus Calmette Guerin (BCG; TheraCys) Very old agent initially developed as vaccine for MTB. Uses: Superficial bladder
More informationSupplementary Table 1 Clinicopathological characteristics of 35 patients with CRCs
Supplementary Table Clinicopathological characteristics of 35 patients with CRCs Characteristics Type-A CRC Type-B CRC P value Sex Male / Female 9 / / 8.5 Age (years) Median (range) 6. (9 86) 6.5 (9 76).95
More informationNature Medicine doi: /nm.3957
Supplementary Fig. 1. p38 alternative activation, IL-21 expression, and T helper cell transcription factors in PDAC tissue. (a) Tissue microarrays of pancreatic tissue from 192 patients with pancreatic
More informationImmune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich
Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3
More informationIpilimumab ASCO Data Review and Discussion Webcast. Monday, June 2, 2008
Ipilimumab ASCO Data Review and Discussion Webcast Monday, June 2, 2008 Slide 2 Forward Looking Statements Except for historical information, the matters contained in this slide presentation may constitute
More informationLevels of peripheral CD4 FoxP3 regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer
GENE THERAPY Levels of peripheral CD4 FoxP3 regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer Xin Yao, 1 Mojgan Ahmadzadeh, 1 Yong-Chen Lu, 1
More informationgp100 (209-2M) peptide and High Dose Interleukin-2 in HLA-A2+ Advanced Melanoma Patients Cytokine Working Group Experience
gp100 (209-2M) peptide and High Dose Interleukin-2 in HLA-A2+ Advanced Melanoma Patients Cytokine Working Group Experience Metastatic Melanoma- Progress in Past 30 years Approved Therapies (USA) Date DTIC
More informationHua Tang, Weiping Cao, Sudhir Pai Kasturi, Rajesh Ravindran, Helder I Nakaya, Kousik
SUPPLEMENTARY FIGURES 1-19 T H 2 response to cysteine-proteases requires dendritic cell-basophil cooperation via ROS mediated signaling Hua Tang, Weiping Cao, Sudhir Pai Kasturi, Rajesh Ravindran, Helder
More informationMATERIALS AND METHODS. Neutralizing antibodies specific to mouse Dll1, Dll4, J1 and J2 were prepared as described. 1,2 All
MATERIALS AND METHODS Antibodies (Abs), flow cytometry analysis and cell lines Neutralizing antibodies specific to mouse Dll1, Dll4, J1 and J2 were prepared as described. 1,2 All other antibodies used
More informationClinical Translation of Immunotherapy using WT1 and CMV specific TCR Gene Transfer
Clinical Translation of Immunotherapy using WT1 and CMV specific Gene Transfer Dr Emma C Morris Reader, Dept of Immunology, UCL Consultant Haematologist (BMT), UCLH and RFH ISCT, 2/5/211 Gene Transfer
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.HNMC.27 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC
Clinical Policy: (Opdivo) Reference Number: CP.HNMC.27 Effective Date: 07.01.17 Last Review Date: 02.18 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy for
More informationNature Immunology: doi: /ni Supplementary Figure 1. RNA-Seq analysis of CD8 + TILs and N-TILs.
Supplementary Figure 1 RNA-Seq analysis of CD8 + TILs and N-TILs. (a) Schematic representation of the tumor and cell types used for the study. HNSCC, head and neck squamous cell cancer; NSCLC, non-small
More informationMelanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1
Melanoma Il parere dell esperto V. Ferraresi Divisione di Oncologia Medica 1 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA209-238 trial) AND
More informationBioassays for Quality Control of Cell & Gene Therapy Products
Bioassays for Quality Control of Cell & Gene Therapy Products Erik Rutjens, Cell & Gene Therapy, Novartis Pharma AG CASSS Bioassays, Silver Spring, March2015 CTL019 Introduction CARTs = Chimeric Antigen
More informationAdoptive Transfer of Vaccine-Induced Peripheral Blood Mononuclear Cells to Patients with Metastatic Melanoma following Lymphodepletion
This information is current as of October 4, 2017. References Subscription Permissions Email Alerts Adoptive Transfer of Vaccine-Induced Peripheral Blood Mononuclear Cells to Patients with Metastatic Melanoma
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationTherapeutic efficacy of MUC1- specific CTL and CD137 costimulation. mammary cancer model. Pinku Mukherjee & Sandra Gendler
Therapeutic efficacy of MUC1- specific CTL and CD137 costimulation in a spontaneous mammary cancer model Pinku Mukherjee & Sandra Gendler Goal of Immunotherapy Boosting the low level anti-tumor immune
More informationPBMC from each patient were suspended in AIM V medium (Invitrogen) with 5% human
Anti-CD19-CAR transduced T-cell preparation PBMC from each patient were suspended in AIM V medium (Invitrogen) with 5% human AB serum (Gemini) and 300 international units/ml IL-2 (Novartis). T cell proliferation
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationSupplemental Information. CD4 + CD25 + Foxp3 + Regulatory T Cells Promote. Th17 Cells In Vitro and Enhance Host Resistance
Immunity, Volume 34 Supplemental Information D4 + D25 + + Regulatory T ells Promote Th17 ells In Vitro and Enhance Host Resistance in Mouse andida albicans Th17 ell Infection Model Pushpa Pandiyan, Heather
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationImmune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group
Immune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group Results of Phase II Study of Durvalumab and Tremelimumab in recurrent clear cell ovarian cancer Trial
More informationChimeric Antigen Receptor - CAR T cell therapy. Frederick L. Locke, MD 2/17/2017
Chimeric Antigen Receptor - CAR T cell therapy Frederick L. Locke, MD 2/17/2017 T cells are immune system cells that normally fight infection Each T cell recognizes a specific target T cells multiply and
More informationCONTRACTING ORGANIZATION: Johns Hopkins University School of Medicine Baltimore, MD 21205
AD Award Number: DAMD7---7 TITLE: Development of Artificial Antigen Presenting Cells for Prostate Cancer Immunotherapy PRINCIPAL INVESTIGATOR: Jonathan P. Schneck, M.D., Ph.D. Mathias Oelke, Ph.D. CONTRACTING
More informationNKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies
NKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies Saul Kivimäe Senior Scientist, Research Biology Nektar Therapeutics NK Cell-Based Cancer Immunotherapy, September 26-27,
More informationNKTR-255: Accessing IL-15 Therapeutic Potential through Robust and Sustained Engagement of Innate and Adaptive Immunity
NKTR-255: Accessing IL-15 Therapeutic Potential through Robust and Sustained Engagement of Innate and Adaptive Immunity Peiwen Kuo Scientist, Research Biology Nektar Therapeutics August 31 st, 2018 Emerging
More informationSupplemental Information. Checkpoint Blockade Immunotherapy. Induces Dynamic Changes. in PD-1 CD8 + Tumor-Infiltrating T Cells
Immunity, Volume 50 Supplemental Information Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1 CD8 + Tumor-Infiltrating T Cells Sema Kurtulus, Asaf Madi, Giulia Escobar, Max Klapholz, Jackson
More informationManagement of Incurable Prostate Cancer in 2014
Management of Incurable Prostate Cancer in 2014 Julie N. Graff, MD, MCR Portland VA Medical Center Assistant Professor of Medicine Knight Cancer Institute, OHSU 2014: Cancer Estimates Stage at Diagnosis
More informationSupplementary Figure 1. Efficiency of Mll4 deletion and its effect on T cell populations in the periphery. Nature Immunology: doi: /ni.
Supplementary Figure 1 Efficiency of Mll4 deletion and its effect on T cell populations in the periphery. Expression of Mll4 floxed alleles (16-19) in naive CD4 + T cells isolated from lymph nodes and
More informationMedia Release. Basel, 26 March 2018
Media Release Basel, 26 March 2018 Phase III IMpower150 study showed Roche s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live
More informationJ Clin Oncol 34: by American Society of Clinical Oncology INTRODUCTION
VOLUME 34 NUMBER 2 JULY 1, 216 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating
More informationNIH Public Access Author Manuscript Science. Author manuscript; available in PMC 2008 March 12.
NIH Public Access Author Manuscript Published in final edited form as: Science. 2006 October 6; 314(5796): 126 129. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes Richard
More informationSummary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain
Summary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain EHA 2017 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://learningcenter.ehaweb.org/eha/#!*listing=3*browseby=2*sortby=1*media=3*ce_id=1181*label=15531
More informationPersonalized medicine - cancer immunotherapy
Personalized medicine - cancer immunotherapy Özcan Met, PhD Senior Staff Scientist, Cell Therapy Director Center for Cancer Immune Therapy Department of Hematology Department of Oncology University Hospital
More informationReuben BENJAMIN, MD, PhD, Principal Investigator
Preliminary Data on Safety, Cellular Kinetics and Anti Leukemic Activity of UCART19, an Allogeneic Anti-CD19 CAR T-cell Therapy in Adult and Pediatric Patients with CD19 + Relapsed/Refractory B-cell Acute
More informationSupplementalgfigureg1gSchematicgdiagramgofgtumor1modellingg
SChinjectionh F:LuchLCLsh IVhinjectionh T:cellsh Monitorhforhtumorh growthhandhxeno: reactivehgvhd GVLgexperimentg kcbgvsgpbgt1cellse Xeno1reactiveg experimentg kcbgvsgpbgt1cellse IVhinjectionh 5xh,N^6
More informationSuppl Video: Tumor cells (green) and monocytes (white) are seeded on a confluent endothelial
Supplementary Information Häuselmann et al. Monocyte induction of E-selectin-mediated endothelial activation releases VE-cadherin junctions to promote tumor cell extravasation in the metastasis cascade
More informationSupplementary Data Table of Contents:
Supplementary Data Table of Contents: - Supplementary Methods - Supplementary Figures S1(A-B) - Supplementary Figures S2 (A-B) - Supplementary Figures S3 - Supplementary Figures S4(A-B) - Supplementary
More informationSupplemental Information. IRF-5 Promotes Cell Death in CD4 T Cells. during Chronic Infection
Cell Reports, Volume 24 Supplemental Information IRF-5 Promotes Cell Death in T Cells during Chronic Infection Aymeric Fabié, Linh Thuy Mai, Xavier Dagenais-Lussier, Akil Hammami, Julien van Grevenynghe,
More information